D. Magirr

发表

A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection

J. Whitehead, D. Magirr, T. Jaki, 2012 .

Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9‐mediated dose requirements of vitamin K antagonist therapy: a pilot study

D. Magirr, M. Brunner, S. Brunner-Ziegler, 2014, British journal of haematology.

Efficacy Evaluation in the Era of Precision Medicine: The Scope for AI

D. Magirr, 2020 .

Simultaneous confidence intervals that are compatible with closed testing in adaptive designs

D Magirr, T Jaki, M Posch, 2013, Biometrika.

On model-based time trend adjustments in platform trials with non-concurrent controls

Marta Bofill Roig, P. Jacko, M. Posch, 2021, 2112.06574.

Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups

D. Magirr, Annabel Allison, F. Alves, 2015, Trials.

Adaptive Survival Trials

M. Posch, D. Magirr, T. Jaki, 2014, 1405.1569.

On model-based time trend adjustments in platform trials with non-concurrent controls

Marta Bofill Roig, P. Jacko, M. Posch, 2021, BMC Medical Research Methodology.

Block response‐adaptive randomization in clinical trials with binary endpoints

Dominic Magirr, D. Magirr, 2011, Pharmaceutical statistics.

Stratified modestly weighted log-rank tests in settings with an anticipated delayed separation of survival curves.

Dominic Magirr, Jos'e L. Jim'enez, D. Magirr, 2022, Biometrical journal. Biometrische Zeitschrift.

Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance

D. Magirr, J. L. Jiménez, 2021, Clinical trials.

Non‐proportional hazards in immuno‐oncology: Is an old perspective needed?

D. Magirr, 2020, Pharmaceutical statistics.

Modestly weighted logrank tests

D. Magirr, C. Burman, 2018, Statistics in medicine.

Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels

M. Posch, D. Magirr, M. Żebrowska, 2015, Statistics in medicine.

Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials

Martin Posch, Thomas Jaki, Franz Koenig, 2016, PloS one.

Influence of genetic background on bleeding phenotype in the tail‐tip bleeding model and recommendations for standardization: communication from the SSC of the ISTH

D. Magirr, M. Schuster, E. Muchitsch, 2014, Journal of thrombosis and haemostasis : JTH.

Visualizing hypothesis tests in survival analysis under anticipated delayed effects

D. Magirr, Jos'e L. Jim'enez, Francesca Gasperoni, 2023, 2304.08087.

The MaxCombo Test Severely Violates the Type I Error Rate.

D. Magirr, C. Burman, 2023, JAMA oncology.

The R Package MAMS for Designing Multi-Arm Multi-Stage Clinical Trials

Philip Pallmann, Thomas Jaki, Dominic Magirr, 2019, Journal of Statistical Software.

Some recommendations for multi-arm multi-stage trials

Thomas Jaki, James Wason, Martin Law, 2012, Statistical methods in medical research.

Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies

D. Magirr, W. Brugger, G. Scarfe, 2019, Cancer Chemotherapy and Pharmacology.

Statistical Methods in Medical Research Some Recommendations for Multi-arm Multi-stage Trials Some Recommendations for Multi-arm Multi-stage Trials

J. Wason, D. Magirr, T. Jaki, 2022 .

NCC: An R-package for analysis and simulation of platform trials with non-concurrent controls

Marta Bofill Roig, P. Jacko, D. Magirr, 2023, SoftwareX.

Flexible sequential designs for multi‐arm clinical trials

N Stallard, D Magirr, T Jaki, 2014, Statistics in medicine.